CD70 as a target in cancer immunotherapy: advances, challenges, and future directions
Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has eme...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1609840/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849762438957760512 |
|---|---|
| author | Ruchen Wu Junze Chen Gang Wang Gang Wang Gang Wang Lulu Han Lulu Han Lulu Han |
| author_facet | Ruchen Wu Junze Chen Gang Wang Gang Wang Gang Wang Lulu Han Lulu Han Lulu Han |
| author_sort | Ruchen Wu |
| collection | DOAJ |
| description | Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation. |
| format | Article |
| id | doaj-art-baeae8d3062c435486cd3dd8759c9726 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-baeae8d3062c435486cd3dd8759c97262025-08-20T03:05:44ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16098401609840CD70 as a target in cancer immunotherapy: advances, challenges, and future directionsRuchen Wu0Junze Chen1Gang Wang2Gang Wang3Gang Wang4Lulu Han5Lulu Han6Lulu Han7Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCenter of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, ChinaJiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCenter of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, ChinaJiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, ChinaCancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation.https://www.frontiersin.org/articles/10.3389/fonc.2025.1609840/fullCD70cancer immunotherapyCAR-T therapymonoclonal antibodiestumor microenvironment |
| spellingShingle | Ruchen Wu Junze Chen Gang Wang Gang Wang Gang Wang Lulu Han Lulu Han Lulu Han CD70 as a target in cancer immunotherapy: advances, challenges, and future directions Frontiers in Oncology CD70 cancer immunotherapy CAR-T therapy monoclonal antibodies tumor microenvironment |
| title | CD70 as a target in cancer immunotherapy: advances, challenges, and future directions |
| title_full | CD70 as a target in cancer immunotherapy: advances, challenges, and future directions |
| title_fullStr | CD70 as a target in cancer immunotherapy: advances, challenges, and future directions |
| title_full_unstemmed | CD70 as a target in cancer immunotherapy: advances, challenges, and future directions |
| title_short | CD70 as a target in cancer immunotherapy: advances, challenges, and future directions |
| title_sort | cd70 as a target in cancer immunotherapy advances challenges and future directions |
| topic | CD70 cancer immunotherapy CAR-T therapy monoclonal antibodies tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1609840/full |
| work_keys_str_mv | AT ruchenwu cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT junzechen cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT gangwang cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT gangwang cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT gangwang cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT luluhan cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT luluhan cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections AT luluhan cd70asatargetincancerimmunotherapyadvanceschallengesandfuturedirections |